Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 30522922

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2019 Jan 19
First author
Horwitz S

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2019 Jan 19;393(10168):201-202. doi: 10.1016/S0140-6736(18)33127-1.
    note
    Source null
    related pmid
    30663580
    relationship
    Comment in
  2. citation
    Lancet. 2019 Jan 19;393(10168):228. doi: 10.1016/S0140-6736(18)33123-4.
    note
    Source null
    related pmid
    30663593
    relationship
    Erratum in
  3. citation
    Ann Oncol. 2022 Mar;33(3):239-241. doi: 10.1016/j.annonc.2021.12.011.
    note
    Source null
    related pmid
    35017032
    relationship
    Comment in

Authors and identifiers

  1. name
    Horwitz S
    type
    Author
  2. name
    O'Connor OA
    type
    Author
  3. name
    Pro B
    type
    Author
  4. name
    Illidge T
    type
    Author
  5. name
    Fanale M
    type
    Author
  6. name
    Advani R
    type
    Author
  7. name
    Bartlett NL
    type
    Author
  8. name
    Christensen JH
    type
    Author
  9. name
    Morschhauser F
    type
    Author
  10. name
    Domingo-Domenech E
    type
    Author
  11. name
    Rossi G
    type
    Author
  12. name
    Kim WS
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Horwitz S
    type
    Author
  2. name
    O'Connor OA
    type
    Author
  3. name
    Pro B
    type
    Author
  4. name
    Illidge T
    type
    Author
  5. name
    Fanale M
    type
    Author
  6. name
    Advani R
    type
    Author
  7. name
    Bartlett NL
    type
    Author
  8. name
    Christensen JH
    type
    Author
  9. name
    Morschhauser F
    type
    Author
  10. name
    Domingo-Domenech E
    type
    Author
  11. name
    Rossi G
    type
    Author
  12. name
    Kim WS
    type
    Author
bibliography ids
  1. nci-bib-1e8b277320d89e930dc077b6
book metadata
content sha256
3451ae39d1730a69b9a10582061e9e3e6e943422a2ceb9336925492b9ae496f2
document type
citation
dois
  1. 10.1016/S0140-6736(18)32984-2
electronic publication date
display
2018 Dec 4
precision
day
year
2018
evidence scope
bibliographic_metadata_only
id
pubmed:30522922
immutable id
pubmed:30522922@3451ae39d1730a69b9a10582061e9e3e6e943422a2ceb9336925492b9ae496f2
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10168
name
Lancet (London, England)
nlm unique id
2985213R
pages
229-240
volume
393
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2019 Jan 19;393(10168):201-202. doi: 10.1016/S0140-6736(18)33127-1.
    note
    Source null
    related pmid
    30663580
    relationship
    Comment in
  2. citation
    Lancet. 2019 Jan 19;393(10168):228. doi: 10.1016/S0140-6736(18)33123-4.
    note
    Source null
    related pmid
    30663593
    relationship
    Erratum in
  3. citation
    Ann Oncol. 2022 Mar;33(3):239-241. doi: 10.1016/j.annonc.2021.12.011.
    note
    Source null
    related pmid
    35017032
    relationship
    Comment in
outcomes validated
false
pmid
30522922
provenance
batch id
438b2803888025c6cf56
provider
NCBI PubMed ESummary
record sha256
bbf5ce0d87187ffb2e85bbc30faa35b90e5d91db65cdf9de8a30e60a4ef352fd
response sha256
0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
retrieved at
2026-09-09T23:47:36.359220+00:00
publication date
display
2019 Jan 19
precision
day
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, N.I.H., Extramural
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/30522922/
title
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Preserved source evidence · Independent clinical review pending · Not medical advice